Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
| Status: | Archived |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
| End Date: | July 2010 |
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease
(PD) to normal control subjects. It is hypothesized that there will be significant
differences in overall amyloid burden in PD patients compared to age-matched normal
controls.
This cross-sectional clinical study will be performed with florbetapir F 18 (18F-AV-45
Injection) followed by brain PET imaging in PD subjects with a range in severity of
cognitive impairment. Subjects with PD will have PET imaging with 18F-AV-45. Results from
PET imaging studies for PD subjects will be compared to 18F-AV-45 PET results for age and
sex matched normal controls drawn from an existing database. Within PD subjects,
correlations between 18F-AV-45 imaging results and clinical tests of motor and
neuropsychological function.
We found this trial at
1
site
3400 Spruce St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
Click here to add this to my saved trials
